JAK Inhibition: The Most Promising Agents in the IBD Pipeline?

Fernández-Clotet, Agnès; Castro-Poceiro, Jesús; Panés, Julián

Fernández-Clotet, Agnès; Castro-Poceiro, Jesús; Panés, Julián.

Affiliation

Fernández-Clotet A; Inflammatory Bowel Disease Group, Institut d'Investigacions Biometiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
Castro-Poceiro J; Inflammatory Bowel Disease Group, Institut d'Investigacions Biometiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
Panés J; Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.

Curr Pharm Des ; 25(1): 32-40, 2019.

Article in En | MEDLINE | ID: mdl-30950344

Subject(s)

Inflammatory Bowel Diseases/drug therapy; Janus Kinases/antagonists & inhibitors; Protein Kinase Inhibitors/therapeutic use; Anti-Inflammatory Agents/therapeutic use; Gastrointestinal Agents/therapeutic use; Humans

Key words

Crohn's disease; Inflammatory bowel disease; JAK inhibitors; Ulcerative colitis; new therapies; small molecules.

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Protein Kinase Inhibitors / Janus Kinases Type of study: Prognostic_studies Limits: Humans Language: En Journal: Curr Pharm Des Journal subject: FARMACIA Year: 2019 Type: Article Affiliation country: Spain

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google